KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
A Web-Based and Mobile Intervention Program Using a Spaced Education Approach for Workplace Mental Health Literacy: Cluster Randomized Controlled Trial.JMIR Ment HealthPMID 38654570PMC110635802024-Apr-230.98未发现恶性肿瘤人群证据。待处理
Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial.Chin Med J (Engl)PMID 38654422PMC110460182024-Apr-200.98未发现恶性肿瘤人群证据。待处理
Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment in Children With Growth Hormone Deficiency.J Clin Endocrinol MetabPMID 38066644PMC110312332024-Apr-190.98未发现恶性肿瘤人群证据。待处理
Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study.J Bone Miner ResPMID 38477751PMC113380452024-Apr-190.98未发现恶性肿瘤人群证据。待处理
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.N Engl J MedPMID 38631003无 PMCID2024-Apr-180.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.Br J DermatolPMID 38226713无 PMCID2024-Apr-170.95The report is for plaque psoriasis, a non-oncology condition. Although it meets other criteria (human, randomized, Phase III, drug intervention, original result), it is not an oncology study and lacks a time-to-event efficacy endpoint.待处理
Malnutrition enteropathy in Zambian and Zimbabwean children with severe acute malnutrition: A multi-arm randomized phase II trial.Nat CommunPMID 38632262PMC110242012024-Apr-170.98未发现恶性肿瘤人群证据。待处理
Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial.J Headache PainPMID 38627638PMC110202092024-Apr-160.98未发现恶性肿瘤人群证据。待处理
Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women Using the Dapivirine Vaginal Ring.J Infect DisPMID 38099506PMC110111742024-Apr-120.98未发现恶性肿瘤人群证据。待处理
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study.RMD OpenPMID 38609322PMC110292422024-Apr-120.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.N Engl J MedPMID 38598794无 PMCID2024-Apr-110.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Clinical and nutritional correlates of bacterial diarrhoea aetiology in young children: a secondary cross-sectional analysis of the ABCD trial.BMJ Paediatr OpenPMID 38604769PMC110152142024-Apr-110.98未发现恶性肿瘤人群证据。待处理
Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes.J Cancer Res Clin OncolPMID 38605258PMC110097702024-Apr-110.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04).J Clin OncolPMID 37861993PMC110958572024-Apr-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.J Clin OncolPMID 38227898PMC110958512024-Apr-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.J Clin OncolPMID 38252907PMC110958642024-Apr-100.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.J Clin OncolPMID 38301187PMC110958862024-Apr-100.95The report is a Phase III randomized trial of a drug (olaparib) in human breast cancer, but the primary and secondary endpoints are patient-reported outcomes (PROs) like fatigue, nausea, and vomiting, measured at fixed time points. It does not report a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or any Kaplan-Meier analysis or hazard ratio for time-to-event).待处理
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2.RMD OpenPMID 38599650PMC110152492024-Apr-100.98未发现恶性肿瘤人群证据。待处理
Influence of vitamin D supplementation on growth, body composition, pubertal development and spirometry in South African schoolchildren: a randomised controlled trial (ViDiKids).BMJ Paediatr OpenPMID 38599800PMC110153022024-Apr-100.98未发现恶性肿瘤人群证据。待处理
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.BMC CancerPMID 38589856PMC110030882024-Apr-080.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer.BMC CancerPMID 38589860PMC110003742024-Apr-080.85This is a protocol for a phase II/III randomized controlled trial in prostate cancer with a time-to-event primary endpoint. However, it is a radiation therapy study with no drug intervention (SABR vs. SABR). Furthermore, it is a protocol without results, not an original result report.待处理
Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial.J Hematol OncolPMID 38589926PMC110030792024-Apr-080.99记录类型属于综述、Meta 分析、社论、评论、病例或指南。待处理
Optimised prevention of postnatal HIV transmission in Zambia and Burkina Faso (PROMISE-EPI): a phase 3, open-label, randomised controlled trial.LancetPMID 38484756无 PMCID2024-Apr-060.98未发现恶性肿瘤人群证据。待处理
Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial.LancetPMID 38490230PMC115564172024-Apr-060.90The trial is eligible for inclusion based on oncology, human, randomized, phase 3, original result, and drug intervention criteria. However, the primary endpoint is quality of life, not a time-to-event efficacy endpoint as required by the adjudication protocol.待处理
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.LancetPMID 38521086无 PMCID2024-Apr-060.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.Neuro OncolPMID 38037691PMC109955042024-Apr-050.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.N Engl J MedPMID 38598573PMC111562872024-Apr-040.98未发现恶性肿瘤人群证据。待处理
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.Signal Transduct Target TherPMID 38565886PMC109875142024-Apr-030.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy for borderline resectable and unresectable colorectal liver metastases: phase II feasibility study.Br J SurgPMID 38608150无 PMCID2024-Apr-030.95The study is a single-arm Phase II feasibility trial, not a randomized Phase III/IIIb or Phase II/III trial. It lacks a randomized control group. The primary endpoint is feasibility (completion of cycles), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, or TTP. The publication type includes 'Clinical Trial, Phase II' and the abstract explicitly states it is a single-arm Phase II study. A subsequent Phase III randomized trial is mentioned as a future direction but is not the subject of this report.待处理
Use of 5-ALA fluorescence-guided surgery versus white-light conventional microsurgery for the resection of newly diagnosed glioblastomas (RESECT study): a French multicenter randomized phase III study.J NeurosurgPMID 37856381无 PMCID2024-Apr-010.90The study is a Phase III randomized trial in human oncology with time-to-event endpoints, but the intervention is not a drug-containing therapeutic intervention for oncological efficacy. 5-ALA is a fluorescent agent used to guide surgery, not a therapeutic drug. The primary endpoint is surgical resection rate. Therefore, it does not meet the drug intervention criterion.待处理
FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation.Clin Cancer ResPMID 38010220PMC109847832024-Apr-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.Int J Gynecol CancerPMID 38129136PMC109826332024-Apr-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Comparison of the Efficacy of HSK3486 and Propofol for Induction of General Anesthesia in Adults: A Multicenter, Randomized, Double-blind, Controlled, Phase 3 Noninferiority Trial.AnesthesiologyPMID 38150544无 PMCID2024-Apr-010.98未发现恶性肿瘤人群证据。待处理
Quantifying Intrafraction Motion and the Impact of Gating for Magnetic Resonance Imaging-Guided Stereotactic Radiation therapy for Prostate Cancer: Analysis of the Magnetic Resonance Imaging Arm From the MIRAGE Phase 3 Randomized Trial.Int J Radiat Oncol Biol PhysPMID 38160916无 PMCID2024-Apr-010.85The record describes a secondary analysis of a Phase III randomized controlled trial (MIRAGE) for prostate cancer, meeting oncology, human, randomized, and phase criteria. However, the abstract does not report survival, progression, recurrence, death, hazard, time-to-event, or closely related efficacy outcomes; it focuses on technical motion analysis and acute toxicity, not definitive efficacy endpoints required for inclusion.待处理
Does Topical Vancomycin Powder Use in Fracture Surgery Change Bacteriology and Antibiotic Susceptibilities? An Analysis of the VANCO Trial.J Orthop TraumaPMID 38206761无 PMCID2024-Apr-010.98未发现恶性肿瘤人群证据。待处理
Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer.J Clin OncolPMID 38215351PMC110035042024-Apr-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).J Clin OncolPMID 38261983PMC116371242024-Apr-010.95While all primary eligibility criteria are met (oncology, human, randomized Phase III, time-to-event endpoint, drug intervention, original result), the report is explicitly identified as an interim analysis. The cohort definition requires 'original formal-result reports', and an interim analysis is typically not considered the final formal result.待处理
Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor-Related Bone Metastases: A Randomized, Double-Blind, Phase 3 Equivalence Trial.JAMA OncolPMID 38329745PMC108538672024-Apr-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.JAMA OncolPMID 38358753PMC108702272024-Apr-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2).MenopausePMID 38517210PMC118960902024-Apr-010.98未发现恶性肿瘤人群证据。待处理
Intravesical Interferon Therapy vs Hyaluronic Acid for Pain Among Female Individuals With Interstitial Cystitis: A Randomized Clinical Trial.JAMA Netw OpenPMID 38587846PMC110026982024-Apr-010.98未发现恶性肿瘤人群证据。待处理
Effectiveness of Group Health Education on "Perceived Stress" among High-School Children of Kolar: A Cluster Randomized Controlled Trial.Indian J Public HealthPMID 38953806无 PMCID2024-Apr-010.98未发现恶性肿瘤人群证据。待处理
KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema.Am J OphthalmolPMID 37460036无 PMCID2024-Apr0.98未发现恶性肿瘤人群证据。待处理
Long-term efficacy and safety of adjunctive perampanel in patients from the Asia-Pacific region with refractory focal-onset seizures in Study 335 open-label extension.Epilepsia OpenPMID 37867420PMC109842842024-Apr0.98未发现恶性肿瘤人群证据。待处理
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study: An analysis with considerations for future studies.J Eur Acad Dermatol VenereolPMID 37907280无 PMCID2024-Apr0.99记录类型属于综述、Meta 分析、社论、评论、病例或指南。待处理
Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores.J Eur Acad Dermatol VenereolPMID 38041556无 PMCID2024-Apr0.98未发现恶性肿瘤人群证据。待处理
Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.Eur J HaematolPMID 38112205无 PMCID2024-Apr0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.J Am Acad DermatolPMID 38122848无 PMCID2024-Apr0.98未发现恶性肿瘤人群证据。待处理
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.Lancet Infect DisPMID 38141632无 PMCID2024-Apr0.98未发现恶性肿瘤人群证据。待处理
Response to Individualized vs. conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.Fertil SterilPMID 38147958无 PMCID2024-Apr0.99记录类型属于综述、Meta 分析、社论、评论、病例或指南。待处理